Share chart Cassava Sciences, Inc.
Extended chart
Simple chart
About Cassava Sciences, Inc.
Cassava Sciences, Inc., биотехнологическая компания, работающая на клинической стадии, разрабатывает лекарства от расстройств нервной системы. Ведущим кандидатом в терапевтический продукт является низкомолекулярный препарат PTI-125, клинические испытания которого завершены в фазе 2b; Кандидат в исследуемый диагностический продукт - это SavaDx, биомаркер крови для диагностики болезни Альцгеймера. Компания ранее называлась Pain Therapeutics, Inc. и сменила название на Cassava Sciences, Inc. в марте 2019 года. Cassava Sciences, Inc. была основана в 1998 году и базируется в Остине, штат Техас. more details| IPO date | 2000-07-14 |
|---|---|
| ISIN | US14817C1071 |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Дивиденд ао | 5.25 |
| Сайт | https://www.cassavasciences.com |
| Цена ао | 1.9 |
| Change price per day: | -5.42% (1.66) |
|---|---|
| Change price per week: | +9.03% (1.44) |
| Change price per month: | -10.29% (1.75) |
| Change price per 3 month: | -37.7% (2.52) |
| Change price per half year: | -94.13% (26.73) |
| Change price per year: | -92.97% (22.34) |
| Change price per 3 year: | -93.1% (22.76) |
| Change price per 5 year: | -50.47% (3.17) |
| Change price per 10 year: | -22.66% (2.03) |
| Change price per year to date: | -33.47% (2.36) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Blackrock Inc. | 3037415 | 7.02 |
| Vanguard Group Inc | 2324626 | 5.38 |
| State Street Corporation | 1069649 | 2.47 |
| Geode Capital Management, LLC | 873996 | 2.02 |
| Gallacher Capital Management LLC | 581606 | 1.34 |
| Morgan Stanley | 541273 | 1.25 |
| COWEN AND COMPANY, LLC | 500000 | 1.16 |
| Northern Trust Corporation | 387666 | 0.9 |
| JANE STREET GROUP, LLC | 374206 | 0.87 |
| Charles Schwab Investment Management, Inc. | 308836 | 0.71 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| iShares Morningstar Small-Cap Growth ETF | 0.03395 | 596.94 | 0.72598 |
| iShares Morningstar Small-Cap ETF | 0.02898 | 391.25 | 1.60498 |
| iShares Morningstar Small-Cap Value ETF | 0.02411 | 197.28 | 2.50476 |
| 0.03 | 395.16 | 1.61 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Eric J. Schoen | Chief Financial Officer | 460k | 1968 (57 years) |
| Mr. Michael Zamloot | Senior Vice President of Technical Operations | N/A | |
| Dr. Lindsay H. Burns Ph.D. | Senior Vice President of Neuroscience | N/A | |
| Dr. James W. Kupiec M.D. | Chief Medical Officer | 435k | 1953 (72 years) |
| Mr. R. Christopher Cook | Senior VP, Company Secretary & General Counsel | 425k | 1964 (61 year) |
| Dr. Michael Marsman Pharm.D. | Senior Vice President of Regulatory Affairs | N/A | |
| Dr. George Thornton Ph.D. | Senior Vice President of Technology | N/A | |
| Mr. Richard Jon Barry | CEO & Director | 1959 (66 years) |
Address: United States, Austin, 7801 North Capital of Texas Highway - open in Google maps, open in Yandex maps
Website: https://www.cassavasciences.com
Website: https://www.cassavasciences.com
